CDK 4/6 Inhibitors as Single Agent in Advanced Solid TumorsFrancesco Schettini, Lucia Del Mastro, Irene De Santo et al.|Frontiers in Oncology|2018Cited by 205
Endocrine treatment versus chemotherapy in postmenopausal women with hormone receptor-positive, HER2-negative, metastatic breast cancer: a systematic review and network meta-analysisMario Giuliano, Daniele Generali, Francesco Schettini et al.|The Lancet Oncology|2019Cited by 193
The evolving therapeutic landscape of trastuzumab-drug conjugates: Future perspectives beyond HER2-positive breast cancerClaudia von Arx, Lucia Del Mastro, Pietro De Placido et al.|Cancer Treatment Reviews|2022Cited by 115
Overall Survival of CDK4/6-Inhibitor–Based Treatments in Clinically Relevant Subgroups of Metastatic Breast Cancer: Systematic Review and Meta-AnalysisFrancesco Schettini, Daniele Generali, Fabiola Giudici et al.|JNCI Journal of the National Cancer Institute|2020Cited by 102
Neutrophil percentage-to-albumin Ratio Predicts Mortality in Bladder Cancer Patients Treated With Neoadjuvant Chemotherapy Followed By Radical CystectomyMatteo Ferro, Mihai Dorin Vartolomei, Dragoș-Florin Babă et al.|Future Science OA|2021Cited by 79